CMR Surgical announced the U.S. FDA has granted marketing authorisation for the Versius Surgical System, paving the way for a next-generation versatile, adaptable, and digitally driven surgical robot to be introduced in the United States. The FDA marketing authorisation of Versius is a significant milestone for CMR as Versius is the first multi-port, soft tissue general surgical Robotic Assisted Surgical Device (RASD) to successfully be authorised through FDA’s De Novo application process. Versius is a RASD intended to assist in the precise and accurate control of Versius Surgical endoscopic instruments and is indicated in the U.S. for adult patients 22 years of age and older, eligible for soft tissue minimal access surgery, for cholecystectomy.
Related: Endostart wins CE mark to bring magnetic balloon tech to enteroscopy
Versius is compact and modular, making it a versatile and portable surgical robot that can seamlessly integrate into virtually any operating room to perform cholecystectomy procedures. It can be easily moved between departments, making it suitable for any care setting. Versius is designed to biomimic the human arm, empowering surgeons through optimised port placement together with the dexterity and accuracy of small, fully wristed instruments. Versius offers 3D HD vision, easy-to-adopt instrument control, and a choice of ergonomic working positions, with an open surgeon console that has the potential to reduce stress and fatigue while allowing for clear communication with the surgical team.
Mark Slack, Chief Medical Officer and Co-founder at CMR Surgical, commented: “Securing FDA marketing authorisation for Versius for use in cholecystectomy in adult patients is a significant milestone for CMR and, most importantly, for hospitals and patients who will now have greater access to robotic-assisted surgery in cholecystectomy procedures. With FDA authorisation, we can now bring our compact and portable surgical robot to the world’s largest healthcare market, expanding the benefits of robotic-assisted surgery with Versius across various care settings in the U.S.”
As a digitally driven system, Versius is rooted in continuous innovation driven through software to ensure customers benefit from the latest technology updates. With a suite of digital apps to support surgeons, surgical teams and hospitals, Versius provides real time insights to improve proficiency and optimise surgical robotic programs. As CMR brings Versius to customers across the U.S., the Company will also roll out its state-of-the art global metrics-based training program. The training pathway draws on cutting-edge technology including Versius Trainer and the Versius eLearning platform, as well as peer to peer education through preceptoring and ongoing guidance and support, ensuring smooth transition from training to the operating room. CMR’s training pathway also includes Versius Virtual Reality and Versius Trainer in VR improving training pathway accessibility.
Massimiliano Colella, Interim Chief Executive Officer at CMR Surgical, added: “The U.S. is an important strategic market so gaining FDA authorisation for Versius for use in cholecystectomy procedures in adult patients is a significant step forward in CMR achieving its mission of bringing minimal access surgery to more patients around the world. The value of Versius as a compact and modular system has been demonstrated by leading hospitals around the world, and we look forward to working closely with hospitals in the U.S. to introduce Versius.”
